平阳霉素、地塞米松联合治疗海绵状血管瘤临床应用

Treatment of cavernous hemangionm with pingyangmycin and dexamethasone

目的 探讨平阳霉素与地塞米松联合应用治疗头面部海绵状血管瘤的临床效果及其作用机制。 方法 对70例海绵状血管瘤患者采用平阳霉素1—8mg、地塞米松磷酸钠1—5mg不等加适量20 mL·L^（-1）利多卡因在血管瘤体外加压后局部注射。 结果 70例患者治愈51列（72．8％），有效17例（24．3％），无效2例（2．9％）。总有效率97．1％。 结论 平阳霉素和地塞米松联合应用治疗海绵状血管瘤有临床应用价值。平阳霉素的作用机制可能是其抑制了血管内皮细胞的合成与代谢，从而导致了变异血管内皮细胞的变性与坏死；地塞米松发挥了辅助作用。抑制了单用平阳霉素所致并发症的发生。

Aim To study the clinical effects and action mechanism of combined use of pingyangmycin and dexamethasone in the treatment of cavernous hemangioma. Methods 70 cases were treated with the combination of 1 ～ 8 mg of pingyangmycin, 1～ 5 mg of dexamethasone and 20ml of Xylocaine, which was injected locally outside the tumor under pressure. Results 51 of 70 cases recovered （72.9%） ; 17 cases improved （24. 3% ） ; 2 cases had no effect （2. 9% ） The total effective rate was 97. 1%. Conclusion It is clinically valuable to treat cavernous hemangioma with pingyangmyein and dexamethasone together, pingyangmycin may inhibit the synthesis and metabolism of endothelial cells of blood vessels, which leads to the death of the abnormal endothelial cells. dexamethasone also works together, which inhibit the complications caused by the use of pingyangmycin only.